Biopharma M&A More than Doubled in Q1 Compared to the Year Prior: Report

The number of biopharma M&A deals more than doubled in the first quarter of 2024 compared to the same period a year ago, exemplifying a top exit route for pre-commercial companies vying for validation and attention. A new report from Leerink Partners released this week tallied 13 biopharma M&A deals in the first quarter of 2024 compared to six in the first quarter of 2023. There were 47 deals in the last twelve months through March 2024, compared to 42 through March 2023. The Leerink M&A team described persistent Big Pharma interest specifically in biotechs focusing on new cancer drugs, namely radiopharmaceutical and antibody-drug conjugate (ADC) makers.

Read the full article: Biopharma M&A More than Doubled in Q1 Compared to the Year Prior: Report //

Source: https://www.fiercebiotech.com/biotech/biopharma-ma-more-doubled-first-quarter-compared-year-prior

Leave a Comment

Your email address will not be published.

Scroll to Top